Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis

Immix Biopharma Inc's IMMX subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for relapsed or refractory multiple myeloma and light chain (AL) amyloidosis. 

Additional NXC-201 clinical data was presented on eight Amyloidosis patients relapsed/refractory to Johnson & Johnson's JNJ Darzalex (daratumumab)-based regimens.

The highlights of the data presented include:

• The overall response rate of 100% (8/8)
• The complete response rate of 63% (5/8) (MRD 10-5)
• The organ response rate of 75% (6/8)
• Zero grade 4 cytokine release syndrome (CRS) events were reported.
• The best responder had a duration of response of 16.5 months as of the data cutoff of May 11, 2023, with the response ongoing.
• Rapid organ response is believed to be related to a fast reduction of free light chain toxicity.

Data demonstrates that BCMA CAR-T therapy is well tolerated and potentially efficacious for advanced, relapsed/refractory AL amyloidosis.

Earlier this month, Immix Biopharma announced early interim data from the IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd BGNE / Novartis AG's NVS tislelizumab, for advanced solid tumors.

100% Tumor Shrinkage at two months was observed in advanced metastatic colorectal cancer demonstrated by IMX-110 + tislelizumab combination in the first cohort of patients who received the lowest IMX-110 dose.

Price Action: IMMX shares are up 4.88% at $1.72 on the last check Monday.